PD-L1 Status in Second-Line Lung Adenocarcinoma

Video

Transcript:Anders Mellemgaard, MD: I think it’s important to test for PD-L1 status. PD-L1 is a fairly good predictor of outcome of immune checkpoint inhibitors. So, in order to select the right treatment for a particular patient, PD-L1 testing is really important. But, other things also go into the evaluation as we try to determine a proper treatment for a particular patient.

An issue that we really have not resolved is, what is the cutoff? When is a patient a good candidate for checkpoint inhibitor treatment, and when is the PD-L1 expression too low? I think we have seen many different cutoffs in clinical trials. It appears that a minimum cutoff of 1% is certainly something that we can use. It’s also quite clear that if we raise the bar, we will be even better at selecting checkpoint inhibitor treatment for patients.

I think it’s quite clear that PD-L1 status predicts the outcome of checkpoint inhibitors. So, the higher the score, the better the outcome can be expected. And that’s not related to toxicity. A patient who has a high PD-L1 expression has a better chance of a good outcome, but does not have an increased risk of toxicity. So, the benefit for the patient really has a lot to do with the particular expression within the tumor of this particular patient.

Martin Reck, MD, PhD: Immunotherapy has become an additional treatment option for our patients with pretreated advanced non—small cell lung cancer. We have seen in two really large trials that there is a relation between the PD-L1 expression and the efficacy of anti–PD-1 antibodies, and this we have seen predominantly in patients with advanced non-squamous non–small cell lung cancer, in patients with pretreated adenocarcinoma. In my practice, when I do have a pretreated patient with adenocarcinoma, I would like to see the PD-L1 expression status. I would like to test my patient for the PD-L1 expression status, because this is one additional instrument for my selection of treatment. So, if I would have a patient in a good shape with a clear PD-L1 negative tumor, I also would think about first giving this patient a chemotherapy as a second-line treatment option.

Transcript Edited for Clarity

Related Videos
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD